CompanyBRVENasdaqSan Francisco, CA

Braveheart Bio, Inc.

Braveheart Bio develops BHB-1893, an oral small-molecule cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy.

SEC EDGAR ClinicalTrials.gov braveheart.bio

SCHEDULE 13D/ASep 10Latest SEC filing

Sep 8Latest story

September 2026

Braveheart Bio starts Phase 3 oHCM trial, reports Q2 2026 results

Sep 8Quarterly updateBraveheart Bio, Inc.

August 2026

Braveheart Bio registers Phase 3 trial of BHB-1893 for obstructive HCM

Aug 10Trial updateBHB-1893 Braveheart Bio, Inc.

Braveheart Bio prices IPO at $18 per share, raising $382.5 million

Aug 6FinancingBraveheart Bio, Inc.

July 2026

Braveheart Bio files for IPO, plans two global Phase 3 trials for HCM drug BHB-1893

Jul 14FinancingBHB-1893 Braveheart Bio, Inc.